MARY MULCAHY, MD
Medical Oncology Physician · CHICAGO, IL
Individual Active NPI 1306870837
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 537 | 187,616 | $19,515,924 | $5,032,680 | $4,007,001 |
| 2023 | 614 | 216,047 | $24,907,344 | $6,055,741 | $4,819,714 |
| 2022 | 1,444 | 197,825 | $20,638,125 | $5,616,385 | $4,542,704 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | 27,180 | $49 | $39 |
| J9263 | Injection, oxaliplatin, 0.5 mg | 15,284 | $0 | $0 |
| J9380 | Injection, teclistamab-cqyv, 0.5 mg | 13,770 | $31 | $25 |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 13,500 | $1 | $1 |
| J1453 | Injection, fosaprepitant, 1 mg | 12,600 | $0 | $0 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 11,384 | $0 | $0 |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 9,740 | $43 | $34 |
| J9271 | Injection, pembrolizumab, 1 mg | 6,600 | $56 | $45 |
| J9299 | Injection, nivolumab, 1 mg | 4,600 | $31 | $24 |
| J9041 | Injection, bortezomib, 0.1 mg | 4,585 | $2 | $1 |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 4,380 | $19 | $15 |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 3,580 | $26 | $21 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Medical Oncology Physician | 207RX0202X | ✓ | 036096205 | IL |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- Yes
Other Medical Oncology Physician providers in Illinois
- NPI 1013273614
- NPI 1891761532
- NPI 1134448665
- NPI 1134205081
- NPI 1619234218
- NPI 1922327535
- NPI 1992948152
- NPI 1295701738
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.